Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity

Manh Cuong Vo, Hyun Ju Lee, Jong Seok Kim, My Dung Hoang, Nu Ri Choi, Joon Haeng Rhee, Vinoth Kumar Lakshmanan, SungJae Shin, Je Jung Lee

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Dendritic cell (DC)-based vaccines are considered useful in cancer immunotherapy, and the interaction of DC and adjuvants is important in the design of the next generation vaccines. In this study, whether DC combined with Rv2299c derived from mycobacteria could improve anti-tumor immune responses in a colon cancer mouse model was evaluated. MC38 cell lines were injected subcutaneously to establish colon-cancer-bearing mice and the following four groups were evaluated: PBS control, tumor antigen (TA) loaded-DC, Rv2299c, and a combination of TA-loaded-DC and Rv2299c. The combination treatment with TA-loaded-DC and Rv2299c exhibited greater inhibition of tumor growth compared to other groups. These effects were associated with the reduction of suppressor cells, such as myeloidderived suppressor cells and regulatory T cells, and the induction of effector cells, such as CD4+ T cells and CD8+ T cells, in spleen, and with the activation of cytotoxic T Lymphocytes and NK cells. These results suggest that TA-loaded-DC vaccination with Rv2299c derived from mycobacteria enhanced anti-tumor immunity in a mouse colon cancer model by inhibiting the generation of immune-suppressive cells and recovering numbers of effector cells, and demonstrated superior polarization of the Th1/Th2 balance in favor of the Th1 immune response.

Original languageEnglish
Pages (from-to)33781-33790
Number of pages10
JournalOncotarget
Volume6
Issue number32
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Toll-Like Receptors
Mycobacterium
Dendritic Cells
Immunity
Vaccination
Neoplasm Antigens
Neoplasms
Colonic Neoplasms
Vaccines
Th1-Th2 Balance
T-Lymphocytes
Cytotoxic T-Lymphocytes
Regulatory T-Lymphocytes
Natural Killer Cells
Immunotherapy
Spleen
Cell Count
Cell Line
Growth

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Vo, M. C., Lee, H. J., Kim, J. S., Hoang, M. D., Choi, N. R., Rhee, J. H., ... Lee, J. J. (2015). Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity. Oncotarget, 6(32), 33781-33790. https://doi.org/10.18632/oncotarget.5281
Vo, Manh Cuong ; Lee, Hyun Ju ; Kim, Jong Seok ; Hoang, My Dung ; Choi, Nu Ri ; Rhee, Joon Haeng ; Lakshmanan, Vinoth Kumar ; Shin, SungJae ; Lee, Je Jung. / Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity. In: Oncotarget. 2015 ; Vol. 6, No. 32. pp. 33781-33790.
@article{bad8034ebb844d65bef50155567955fc,
title = "Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity",
abstract = "Dendritic cell (DC)-based vaccines are considered useful in cancer immunotherapy, and the interaction of DC and adjuvants is important in the design of the next generation vaccines. In this study, whether DC combined with Rv2299c derived from mycobacteria could improve anti-tumor immune responses in a colon cancer mouse model was evaluated. MC38 cell lines were injected subcutaneously to establish colon-cancer-bearing mice and the following four groups were evaluated: PBS control, tumor antigen (TA) loaded-DC, Rv2299c, and a combination of TA-loaded-DC and Rv2299c. The combination treatment with TA-loaded-DC and Rv2299c exhibited greater inhibition of tumor growth compared to other groups. These effects were associated with the reduction of suppressor cells, such as myeloidderived suppressor cells and regulatory T cells, and the induction of effector cells, such as CD4+ T cells and CD8+ T cells, in spleen, and with the activation of cytotoxic T Lymphocytes and NK cells. These results suggest that TA-loaded-DC vaccination with Rv2299c derived from mycobacteria enhanced anti-tumor immunity in a mouse colon cancer model by inhibiting the generation of immune-suppressive cells and recovering numbers of effector cells, and demonstrated superior polarization of the Th1/Th2 balance in favor of the Th1 immune response.",
author = "Vo, {Manh Cuong} and Lee, {Hyun Ju} and Kim, {Jong Seok} and Hoang, {My Dung} and Choi, {Nu Ri} and Rhee, {Joon Haeng} and Lakshmanan, {Vinoth Kumar} and SungJae Shin and Lee, {Je Jung}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5281",
language = "English",
volume = "6",
pages = "33781--33790",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "32",

}

Vo, MC, Lee, HJ, Kim, JS, Hoang, MD, Choi, NR, Rhee, JH, Lakshmanan, VK, Shin, S & Lee, JJ 2015, 'Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity', Oncotarget, vol. 6, no. 32, pp. 33781-33790. https://doi.org/10.18632/oncotarget.5281

Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity. / Vo, Manh Cuong; Lee, Hyun Ju; Kim, Jong Seok; Hoang, My Dung; Choi, Nu Ri; Rhee, Joon Haeng; Lakshmanan, Vinoth Kumar; Shin, SungJae; Lee, Je Jung.

In: Oncotarget, Vol. 6, No. 32, 01.01.2015, p. 33781-33790.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity

AU - Vo, Manh Cuong

AU - Lee, Hyun Ju

AU - Kim, Jong Seok

AU - Hoang, My Dung

AU - Choi, Nu Ri

AU - Rhee, Joon Haeng

AU - Lakshmanan, Vinoth Kumar

AU - Shin, SungJae

AU - Lee, Je Jung

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Dendritic cell (DC)-based vaccines are considered useful in cancer immunotherapy, and the interaction of DC and adjuvants is important in the design of the next generation vaccines. In this study, whether DC combined with Rv2299c derived from mycobacteria could improve anti-tumor immune responses in a colon cancer mouse model was evaluated. MC38 cell lines were injected subcutaneously to establish colon-cancer-bearing mice and the following four groups were evaluated: PBS control, tumor antigen (TA) loaded-DC, Rv2299c, and a combination of TA-loaded-DC and Rv2299c. The combination treatment with TA-loaded-DC and Rv2299c exhibited greater inhibition of tumor growth compared to other groups. These effects were associated with the reduction of suppressor cells, such as myeloidderived suppressor cells and regulatory T cells, and the induction of effector cells, such as CD4+ T cells and CD8+ T cells, in spleen, and with the activation of cytotoxic T Lymphocytes and NK cells. These results suggest that TA-loaded-DC vaccination with Rv2299c derived from mycobacteria enhanced anti-tumor immunity in a mouse colon cancer model by inhibiting the generation of immune-suppressive cells and recovering numbers of effector cells, and demonstrated superior polarization of the Th1/Th2 balance in favor of the Th1 immune response.

AB - Dendritic cell (DC)-based vaccines are considered useful in cancer immunotherapy, and the interaction of DC and adjuvants is important in the design of the next generation vaccines. In this study, whether DC combined with Rv2299c derived from mycobacteria could improve anti-tumor immune responses in a colon cancer mouse model was evaluated. MC38 cell lines were injected subcutaneously to establish colon-cancer-bearing mice and the following four groups were evaluated: PBS control, tumor antigen (TA) loaded-DC, Rv2299c, and a combination of TA-loaded-DC and Rv2299c. The combination treatment with TA-loaded-DC and Rv2299c exhibited greater inhibition of tumor growth compared to other groups. These effects were associated with the reduction of suppressor cells, such as myeloidderived suppressor cells and regulatory T cells, and the induction of effector cells, such as CD4+ T cells and CD8+ T cells, in spleen, and with the activation of cytotoxic T Lymphocytes and NK cells. These results suggest that TA-loaded-DC vaccination with Rv2299c derived from mycobacteria enhanced anti-tumor immunity in a mouse colon cancer model by inhibiting the generation of immune-suppressive cells and recovering numbers of effector cells, and demonstrated superior polarization of the Th1/Th2 balance in favor of the Th1 immune response.

UR - http://www.scopus.com/inward/record.url?scp=84946013723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946013723&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5281

DO - 10.18632/oncotarget.5281

M3 - Article

VL - 6

SP - 33781

EP - 33790

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -